13 citations
,
June 2012 in “Dermatologic Surgery” This review discusses treatment strategies for managing scarring based on severity using volume, surface, and movement interventions, but does not present new experimental results.
1 citations
,
December 2012 in “Journal of dermatological science” This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
15 citations
,
December 2011 in “Journal of the European Academy of Dermatology and Venereology” In this study, severe diffuse hair loss in patients with systemic lupus erythematosus was associated with distinct clinical, dermoscopic, and histopathological features, which improved alongside treatment of the underlying condition.
May 2026 in “SKIN The Journal of Cutaneous Medicine” This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.